Biologics by McKesson Named the Exclusive Pharmacy for FDA- Approved SKYCLARYS (omaveloxolone) for the Treatment of Friedreich ’s Ataxia

CARY, N.C., April 5, 2023 — Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare diseases, was selected by Reata Pharmaceuticals as the sole specialty pharmacy provider for SKYCLARYSTM (omaveloxolone), the first and only treatment for Friedreich’s ataxia (FA). S...
Source: McKesson News - Category: Information Technology Source Type: news